BC
WVE icon

Bridgefront Capital’s Wave Life Sciences WVE Stock Holding History

Bridgefront Capital’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.1K Buy
+12,146
New +$158K 0.02% 502

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bridgefront Capital's WVE Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Wave Life Sciences (WVE) in Q1 2026: 12,146 shares worth $88.1K. The stake represents 0.02% of the portfolio and ranks #502 among its holdings.

230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Bridgefront Capital held 12,146 shares of Wave Life Sciences worth $88.1K as of Q1 2026.
  • Wave Life Sciences was a new Bridgefront Capital position in Q1 2026.
  • Wave Life Sciences made up 0.02% of Bridgefront Capital's portfolio in Q1 2026, its #502 holding.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.